内幕交易金额近亿元，原董事长被罚500万，新诺威回应

Core Viewpoint - The announcement reveals that the former chairman of New Nuo Wei, Pan Weidong, engaged in insider trading involving nearly 100 million yuan, leading to a fine of 5 million yuan from the China Securities Regulatory Commission (CSRC) [1] Group 1: Company Actions - Shiyao Group's subsidiary, New Nuo Wei, plans to acquire another subsidiary, Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd., and raise supporting funds [1] - The major shareholder of New Nuo Wei, Enbi Pu Pharmaceutical Co., Ltd., intends to increase its stake in New Nuo Wei by up to 100 million yuan within six months [1] Group 2: Regulatory Actions - The CSRC determined that the acquisition transaction was insider information prior to its public announcement, and Pan Weidong was aware of this information before December 5, 2023 [1] - Pan Weidong purchased 2.74258 million shares of New Nuo Wei using Enbi Pu's securities account during the sensitive period, amounting to approximately 99.9888 million yuan [1] - The CSRC ordered Pan Weidong to legally handle the illegally held securities and imposed a fine of 5 million yuan [1] Group 3: Company Response - New Nuo Wei's securities department confirmed that Pan Weidong's resignation as chairman on September 23, 2024, was unrelated to the insider trading investigation [1] - The company did not issue any announcements regarding the resignation as the relevant personnel are no longer affiliated with the company [1]